US 11,776,664 B2
Method to use gene expression to determine likelihood of clinical outcome of renal cancer
Wayne Cowens; Steven Shak, Hillsborough, CA (US); Audrey Goddard, San Francisco, CA (US); Dejan Knezevic, Palo Alto, CA (US); Joffre Baker, Montara, CA (US); Michael C. Kiefer, Walnut Creek, CA (US); Tara Maddala, Sunnyvale, CA (US); and Frederick L. Baehner, San Francisco, CA (US)
Assigned to Genomic Health, Inc., Redwood City, CA (US)
Filed by Genomic Health, Inc., Redwood City, CA (US)
Filed on Nov. 19, 2020, as Appl. No. 16/952,566.
Application 16/952,566 is a continuation of application No. 15/368,979, filed on Dec. 5, 2016, granted, now 10,892,038.
Application 15/368,979 is a continuation of application No. 12/987,023, filed on Jan. 7, 2011, granted, now 9,551,034, issued on Jan. 24, 2017.
Claims priority of provisional application 61/294,038, filed on Jan. 11, 2010.
Claims priority of provisional application 61/346,230, filed on May 19, 2010.
Prior Publication US 2021/0166790 A1, Jun. 3, 2021
Prior Publication US 2022/0051755 A9, Feb. 17, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/574 (2006.01); G16B 99/00 (2019.01); G16B 25/10 (2019.01); G06N 7/01 (2023.01)
CPC G16B 99/00 (2019.02) [G01N 33/57438 (2013.01); G06N 7/01 (2023.01); G16B 25/10 (2019.02); C12Q 2600/112 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/158 (2013.01)] 20 Claims
 
1. A method of analyzing the expression of RNA transcripts of genes in a human renal cancer patient, the method comprising:
measuring levels of RNA transcripts, in a renal tumor sample from the patient, of a panel of genes consisting of:
a set of genes consisting of one or more angiogenesis genes selected from: ADD1, ANGPTL3, APOLD1, CEACAM1, EDNRB, EMCN, ENG, EPAS1, FLT1, JAG1, KDR, KL, LDB2, NOS3, NUDT6, PPAP2B, PRKCH, PTPRB, RGS5, SHANK3, SNRK, TEK, ICAM2, and VCAM1;
a set of genes consisting of one or more immune response genes selected from: CCL5, CCR7, CD8A, CX3CL1, CXCL10, CXCL9, HLA-DPB1, IL6, IL8, and SPP1; and
a set of genes consisting of one or more cell cycle genes selected from: BUB1, C13orf15, CCNB1, PTTG1, TPX2, LMNB1, and TUBB2A;
EIF4EBP1; and
a set of genes consisting of one or more reference genes.